Sandra Obikawa Kyosen

Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships

Nouriya Al‐Sannaa, Luisa Bay, Deborah Barbouth et al. · Orphanet Journal of Rare Diseases · 2015 · 79 citations · Full text

Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: From our experience of 4 cases including an autopsy case

Hiroshi Kobayashi, Yohta Shimada, Masahiro Ikegami et al. · Molecular Genetics and Metabolism · 2010 · 57 citations

Prognostic Factors, Enzyme Replacement Therapy, Clinical Epidemiology +5

Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age

Christina Lampe, Andrea M. Atherton, Barbara K. Burton et al. · JIMD Reports · 2014 · 46 citations · Full text

Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction

Sandra Obikawa Kyosen, Sayoko Iizuka, Hiroshi Kobayashi et al. · Gene Therapy · 2009 · 35 citations

Neurovirology, Glycogen Reduction, Immunology +6

Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center

Gustavo Antônio Moreira, Sandra Obikawa Kyosen, Camilla L. Patti et al. · Sleep And Breathing · 2014 · 35 citations

Mucopolysaccharidosis Types, Sleep, Sleep Disorder +6